MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$944,298
Unit: Dollar
Positive Cash Flow Breakdown
Stock based compensation
Accounts payable
Impairment of intangible assets
Depreciation expense
Negative Cash Flow Breakdown
Net income (loss)
Prepaid expenses
Accrued liabilities
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-09-30
Cash received in acquisition of phytanix bio
0
0
-943,180
Cash spent on unwind of phytanix bio acquisition
-
310,000
-
Purchase of fixed assets
-
3,297
-
Net cash provided by investing activities
0
-313,297
943,180
Increase in note payable for acquisition of phytanix bio
0
533,898
-
Net proceeds from notes payable
0
-
-
Proceeds from sale of common stock
0
0
395,474
Proceeds from exercise of warrants
0
-2
3,949,732
Proceeds from related party loans
0
0
62,347
Net cash provided by financing activities
0
-533,900
4,407,553
Amortization of debt discount to interest expense
0
1,324,126
243,353
Stock based compensation
-
-
230,995
Gain/loss on disposal of subsidiary
-
7,310,719
-
Derivative expense
0
0
-343,399
Increase in note payable for acquisition of phytanix bio
-
-
583,880
Gain/loss on extinguishment of debt
-
-1,117,778
-
Change in fair value of derivative liabilities
0
3,438,114
-1,930,245
Inventories
0
-11
37
Vat receivable
0
-8,180
-29,481
Net income (loss)
-963,616
7,294,996
-5,927,019
Stock based compensation
67,012
418,589
-
Impairment of intangible assets
13,337
-
-
Prepaid expenses
110,478
-57,231
3,838
Accounts payable
50,173
1,216,082
-177,180
Accrued liabilities
-9,038
-141,491
158,912
Depreciation expense
8,312
24,072
25,143
Net cash used in operating activities
-944,298
-244,134
-2,562,666
Net increase in cash
-944,298
-1,091,331
2,788,067
Effect of exchange rate adjustments on cash
1,105
-121,942
-80,147
Cash, beginning of period
1,509,178
2,722,451
14,531
Cash, end of period
565,985
1,509,178
2,722,451
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase in cash
-$944,298
Stock based
compensation
$67,012
Accounts payable
$50,173
Impairment of intangible
assets
$13,337
Depreciation expense
$8,312
Net cash used in
operating activities
-$944,298
Canceled cashflow
$138,834
Net income (loss)
-$963,616
Prepaid expenses
$110,478
Accrued liabilities
-$9,038
Buy us a coffee
Protagenic Therapeutics, Inc. new (PTIX)
Protagenic Therapeutics, Inc. new (PTIX)